Drug intelligence / Profile preview

erucin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Dietary
01

Overview

Erucin is a naturally occurring isothiocyanate, specifically 4-methylthiobutyl isothiocyanate, found predominantly in cruciferous vegetables such as arugula (Eruca sativa) and related Brassicaceae plants. It is formed by the enzymatic hydrolysis of its precursor, glucoerucin, a glucosinolate. Erucin possesses potent antioxidative, anti-inflammatory, neuroprotective, anticancer chemotherapeutic, and chemopreventive properties. Mechanistically, it induces cellular phase II detoxification enzymes (e.g., glutathione transferase, quinone reductase), inhibits proliferation and induces apoptosis in cancer cells (notably via the p53 and p21 pathways and PARP-1 cleavage), and suppresses inflammatory mediators such as IL-6, IL-1β, TNF-α, iNOS, and COX-2. It has shown activity inhibiting telomerase and reducing tumor growth in various cancer models, as well as neuroprotective effects in cellular models of Parkinson’s disease through Nrf2 activation and increased glutathione levels. It may involve direct or indirect modulation of targets such as the nuclear factor erythroid 2-related factor 2 (Nrf2), nuclear factor NF-κB p105 subunit (NF-κB), and transient receptor potential channels[1][2][3][5][7].

Other names
4-methylthiobutyl isothiocyanate4-(methylthio)butyl isothiocyanate1-isothiocyanato-4-methylsulfanylbutane(4-isothiocyanatobutyl)(methyl)sulfaneCTE370DL3UCTE-370DL3UCTE 370DL3UCCRIS 9056CCRIS9056CCRIS-90564-(methylthiol)-1-(isothiocyanato)butanebutane 1-isothiocyanato-4-(methylthio)-1-isothiocyanato-4-(methylsulfanyl)butane4430-36-8
02

Targets

NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)KEAP1 (Kelch-like ECH-associated protein 1)NF-κBTRPA1 (Transient receptor potential cation channel subfamily A member 1)

Beyond the preview

Go deeper on erucin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on erucin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call